Ascorbate ferrireductase (transmembrane)
Ascorbate ferrireductase (transmembrane) (EC 1.16.5.1, cytochrome b561) is an enzyme with systematic name Fe(III):ascorbate oxidorectuctase (electron-translocating).[1][2][3][4][5][6] This enzyme catalyses the following chemical reaction
Ascorbate ferrireductase (transmembrane) | |||||||||
---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||
EC no. | 1.16.5.1 | ||||||||
Databases | |||||||||
IntEnz | IntEnz view | ||||||||
BRENDA | BRENDA entry | ||||||||
ExPASy | NiceZyme view | ||||||||
KEGG | KEGG entry | ||||||||
MetaCyc | metabolic pathway | ||||||||
PRIAM | profile | ||||||||
PDB structures | RCSB PDB PDBe PDBsum | ||||||||
|
Ascorbate ferrireductase is a diheme cytochrome that acts on hexacyanoferrate(III) and other ferric chelates.
Ferric Fe(III) and Ferrous Fe(II) Solubility
editUsing the conversion of ascorbate (Vitamin C) to monodehydroascorbate is essential when the ferric Fe(III) ion is converted to ferrous Fe(II).The Fe(III) species is insoluble, hence becoming one of the most problematic metal species to introduce and dissolve into an organism's system.[7] Especially in eukaryotes such as humans, fungi, and bacteria, the upcycle of ascorbate is very important as well as the bioavailability of the ferrous (II) ion. There are three ways to increase the solubility of Iron (III) and overcome that challenge: chelation, reduction, and acidification.
Chelation
editChelation can increase the solubility of the iron (III) by coupling 'siderophore ligands' to the Iron species in its solid state to make it transform into an aqueous species. Especially in bacteria, and fungi, siderophores have a very strong binding affinity to Fe3+ and does not bind to other metal ions that may be present. The following is a general chemical equation to represent the process of chelation: A structure of a siderophore. The phenyls with two hydroxyl groups are the binding spots. These iron complexes binds to a receptor on an iron transport that is unique to the siderophore used. The receptor dissociates once it nears the cell's membrane which creates an aqueous ferric Fe(III) ion that can either be used for uptake or reduced to Fe2+ where transporters specific to that ion can transport it instead.
Reduction
editReducing the ferrous (III) ion to ferrous (II) increases the bio availability which improves the rate and extent at which the aqueous soluble ferrous (II) iron will reach the system of the organism and will prevent the mineralization of the aqueous ferrous (III). The general for a following reduction in relation to an iron complex is as follows:
Once the iron complex nears the cell surface, the Iron (II) ion becomes susceptible to accept water ligands, thus hydrating the ion. This process usually occurs in aerobic environments where the Iron (II) ion is also favored. Once the complex is reduced, it must be then re-oxidized in proximity to the cell membrane because it contains binding sites typically only for Iron (III) ions that the protein will then undergo conformational changes to transition to the other side of the membrane.[8]
There are some transporters that allow the Iron (II) ions to be transported directly such as the Fet4, Dmt1, and the Irt1, however these transporters aren't exactly selective as they provide difficulty in binding to the Iron (II) ion so other ions bind as well such as Zn(II), Mn(II), and Cd(II).[9] Transportation like this mainly takes place in plants and in anaerobic environments where oxidation back to the Iron (III) species is impossible.[10]
References
edit- ^ Flatmark T, Terland O (December 1971). "Cytochrome b 561 of the bovine adrenal chromaffin granules. A high potential b-type cytochrome". Biochimica et Biophysica Acta (BBA) - Bioenergetics. 253 (2): 487–91. doi:10.1016/0005-2728(71)90052-1. PMID 4332308.
- ^ McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ (March 2001). "An iron-regulated ferric reductase associated with the absorption of dietary iron". Science. 291 (5509): 1755–9. doi:10.1126/science.1057206. PMID 11230685. S2CID 44351106.
- ^ Su D, Asard H (August 2006). "Three mammalian cytochromes b561 are ascorbate-dependent ferrireductases". The FEBS Journal. 273 (16): 3722–34. doi:10.1111/j.1742-4658.2006.05381.x. PMID 16911521. S2CID 23331329.
- ^ Bérczi A, Su D, Asard H (April 2007). "An Arabidopsis cytochrome b561 with trans-membrane ferrireductase capability" (PDF). FEBS Letters. 581 (7): 1505–8. doi:10.1016/j.febslet.2007.03.006. hdl:10067/629620151162165141. PMID 17376442. S2CID 40210419.
- ^ Wyman S, Simpson RJ, McKie AT, Sharp PA (June 2008). "Dcytb (Cybrd1) functions as both a ferric and a cupric reductase in vitro". FEBS Letters. 582 (13): 1901–6. doi:10.1016/j.febslet.2008.05.010. PMID 18498772.
- ^ Glanfield A, McManus DP, Smyth DJ, Lovas EM, Loukas A, Gobert GN, Jones MK (November 2010). "A cytochrome b561 with ferric reductase activity from the parasitic blood fluke, Schistosoma japonicum". PLOS Neglected Tropical Diseases. 4 (11): e884. doi:10.1371/journal.pntd.0000884. PMC 2982821. PMID 21103361.
- ^ Srai SK, Bomford A, McArdle HJ (June 2002). "Iron transport across cell membranes: molecular understanding of duodenal and placental iron uptake". Best Practice & Research. Clinical Haematology. 15 (2): 243–59. doi:10.1016/s1521-6926(02)90003-4. PMID 12401306.
- ^ Nicklaus MC, Wang S, Driscoll JS, Milne GW (April 1995). "Conformational changes of small molecules binding to proteins". Bioorganic & Medicinal Chemistry. 3 (4): 411–28. doi:10.1016/0968-0896(95)00031-b. PMID 8581425.
- ^ Waters BM, Eide DJ (September 2002). "Combinatorial control of yeast FET4 gene expression by iron, zinc, and oxygen". The Journal of Biological Chemistry. 277 (37): 33749–57. doi:10.1074/jbc.m206214200. PMID 12095998.
- ^ Garrick MD (February 2011). "Human iron transporters". Genes & Nutrition. 6 (1): 45–54. doi:10.1007/s12263-010-0184-8. PMC 3040799. PMID 21437029.
External links
edit- Ascorbate+ferrireductase+(transmembrane) at the U.S. National Library of Medicine Medical Subject Headings (MeSH)